Updated: January 29, 2026
Alternatives to Sinemet If You Can't Fill Your Prescription
Author
Peter Daggett

Summarize with AI
Can't find Sinemet (carbidopa/levodopa)? From dopamine agonists to newer ER formulations, here are the real alternatives your doctor can prescribe.
Sinemet (carbidopa/levodopa) is the most effective treatment for Parkinson's disease—but supply issues, especially with extended-release formulations, mean some patients can't get a fill when they need one. If you're in that situation, you have more options than you might realize.
Important: Never stop carbidopa/levodopa abruptly. Sudden discontinuation can cause a dangerous syndrome involving high fever, muscle rigidity, and rapid neurological decline. Always work with your neurologist when changing Parkinson's medications. This article is a guide for conversations with your doctor—not a substitute for medical advice.
Option 1: Switch Formulations (Same Drug, Different Form)
If the extended-release version of carbidopa/levodopa is unavailable, your doctor may switch you to immediate-release (IR) tablets, which are generally easier to find. IR tablets have a shorter duration of action, so you will need to take them more frequently—typically every 3–4 hours instead of every 6–8 hours. Your neurologist can calculate the correct equivalent dose.
Alternatively, newer extended-release capsule formulations are available and currently not in shortage:
Rytary (carbidopa/levodopa ER capsules): Available in four strengths. Uses a multi-bead technology delivering both immediate-release and extended-release components. Allows for 3–5 doses per day. Not a 1:1 conversion from IR tablets—your doctor will follow manufacturer dosing tables. Usually requires prior authorization.
Crexont (carbidopa/levodopa ER capsules, approved 2024): The newest extended-release carbidopa/levodopa formulation. Allows for twice-daily dosing in many patients. May be available when ER tablets are not.
Option 2: Dopamine Agonists (Different Mechanism)
Dopamine agonists stimulate dopamine receptors in the brain directly, without needing to convert to dopamine first. They are not as potent as levodopa for controlling motor symptoms but are widely available and generally well tolerated. They are most useful as a supplement to levodopa or as a bridge when levodopa is unavailable.
Pramipexole (Mirapex): Available as immediate-release and extended-release tablets. Effective for both motor symptoms and restless legs syndrome. Can cause somnolence, edema, and impulse control issues (gambling, hypersexuality). Used in early PD as monotherapy to delay levodopa initiation.
Ropinirole (Requip): Similar to pramipexole; available in standard and extended-release (Requip XL) formulations. Once-daily dosing with the XL version improves adherence. Similar side effect profile to pramipexole.
Rotigotine (Neupro patch): A once-daily transdermal patch that delivers rotigotine continuously through the skin. Useful for patients who have difficulty swallowing tablets. Provides stable drug levels without the peaks and troughs of oral dosing.
Option 3: MAO-B Inhibitors (Extend Dopamine Activity)
Monoamine oxidase type B (MAO-B) inhibitors work by blocking the enzyme that breaks down dopamine in the brain. They don't add dopamine—they make the dopamine you have (or get from levodopa) last longer. They are typically used in combination with levodopa, or as mild monotherapy in early Parkinson's disease.
Rasagiline (Azilect): Once-daily tablet. More selective and better tolerated than older MAO-B inhibitors. Used as adjunct therapy to reduce 'off' time when combined with levodopa.
Selegiline (Eldepryl): An older MAO-B inhibitor available as a tablet or orally disintegrating tablet (Zelapar). Also used as adjunct therapy. Note: has more drug interactions than rasagiline.
Option 4: COMT Inhibitors (Extend Levodopa Effect)
COMT (catechol-O-methyltransferase) inhibitors block an enzyme that breaks down levodopa in the bloodstream. Taking a COMT inhibitor with your carbidopa/levodopa can extend the duration of each dose—effectively helping you get more out of less. This is not a standalone replacement but can reduce your daily levodopa requirement.
Stalevo: A combination pill containing carbidopa, levodopa, and entacapone (a COMT inhibitor). Taken in place of each carbidopa/levodopa dose, it extends each dose's duration and may be available when standard formulations are not.
What to Tell Your Doctor
When Sinemet is unavailable, bring this information to your neurologist appointment or telehealth call:
Your current formulation, dose, and how many times per day you take it
Which pharmacies you have already checked and what they had (or didn't have)
Any other Parkinson's medications you currently take (to check for interactions)
Your insurance plan, so your doctor knows which alternatives may be covered
Before giving up on your current medication, try using medfinder to check which nearby pharmacies have your exact formulation in stock. You can also read our guide on how to find Sinemet in stock near you for additional tips.
Frequently Asked Questions
The most common alternative is switching between formulations of the same drug—for example, from extended-release tablets to immediate-release tablets, which are more widely available. Immediate-release carbidopa/levodopa requires more frequent dosing but is the same active medication. Your neurologist can help calculate the equivalent dose.
Not for most patients with moderate to advanced Parkinson's disease. Dopamine agonists like pramipexole (Mirapex) and ropinirole (Requip) are useful supplements or early-stage alternatives, but they are generally less effective than levodopa for controlling motor symptoms in established disease. They can serve as a bridge while you locate your medication.
Rytary contains the same active ingredients as Sinemet (carbidopa and levodopa) but uses a different extended-release bead technology. It is not a 1:1 substitution—your doctor must calculate the correct Rytary dose using a conversion table. Rytary is generally available and not in shortage, but it is more expensive and often requires prior authorization.
Crexont is a newer extended-release carbidopa/levodopa capsule approved by the FDA in 2024. It uses multi-bead technology providing both immediate and sustained release, allowing twice-daily dosing for many patients. It is not in shortage and may be an option if ER tablets are unavailable, though cost and insurance coverage vary.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Sinemet also looked for:
More about Sinemet
30,831 have already found their meds with Medfinder.
Start your search today.





